Trials / Completed
CompletedNCT02566369
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,208 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Detailed description
Clinical Trial for each subject is approximately 14 weeks and are randomized to one of the two treatments for 12 weeks. Subjects must be 9 years of age and older with acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD5789 (trifarotene) 50μg/g cream | CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks. |
| DRUG | Placebo cream | Placebo cream applied once daily for 12 weeks |
Timeline
- Start date
- 2015-11-30
- Primary completion
- 2017-11-14
- Completion
- 2017-11-14
- First posted
- 2015-10-02
- Last updated
- 2019-11-12
- Results posted
- 2019-08-22
Locations
124 sites across 5 countries: United States, Canada, Germany, Hungary, Puerto Rico
Source: ClinicalTrials.gov record NCT02566369. Inclusion in this directory is not an endorsement.